Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Key findings from AstraZeneca's phase II studies of ticagrelor

AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.

18 Nov 2009

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.

18 Nov 2009

First gene expression test for coronary artery disease

The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain.

18 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.

17 Nov 2009

Sudden cardiac death more predictable in men than women

A woman who suffers sudden cardiac arrest is significantly less likely than a man to exhibit the decrease in the heart's pumping ability that is widely recognized as a precursor, says a new study in the Nov. 24 Journal of the American College of Cardiology.

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.

16 Nov 2009

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Cappella, Inc., a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the start of Sideguard 3, an IVUS/OCT evaluation of the Sideguard® Coronary Sidebranch Stent & Delivery System. This is a European multicenter study to evaluate the vascular response to Sideguard in de novo bifurcation lesions of native coronary arteries.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

UOHI to receive $5.4M federal funds for development of new alternative radioisotope imaging tracers

Researchers from the University of Ottawa Heart Institute (UOHI) will receive nearly half of a $5.4 million federal fund to help solve a shortage of medical isotopes resulting from the shutdown of the Chalk River nuclear reactor. Two research teams will develop two new alternative radioisotope imaging tracers, test new applications for their use in diagnosing heart disease, and fast track production and distribution as quickly as possible across Canada.

10 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

Stereotaxis reports $13.3 million revenue for third quarter 2009

Stereotaxis, Inc. today reported strong revenue growth, a significant increase in the gross margin, lower operating expenses and a significant reduction in the net loss for both the quarter and the nine month period ended September 30, 2009.

5 Nov 2009

Statins may have negative effects on some cardiac patients, says study

Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance.

4 Nov 2009

John Simpson named the 2009 Distinguished Alumnus for his invention

Back in the 1970s, while watching an angioplasty to widen clogged coronary arteries, John Simpson, Ph.D., M.D., thought there had to be an easier way to perform the procedure.

31 Oct 2009

Celsius RMT ThermoCool catheter of Stereotaxis receives CE Mark for distribution in the European market

Stereotaxis received notice that the Celsius® RMT ThermoCool® catheter has received CE Mark for distribution in the European market. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for use in the Niobe Magnetic Navigation System (MNS).

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

Dramatic reductions in hospitalization for heart attacks and in the need for revascularization surgery were achieved in angina patients treated with the selective heart rate reduction medication ivabradine on top of current standard treatment, according to results of a major clinical study presented today at the 2009 Canadian Cardiovascular Congress in Edmonton.

29 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Cappella introduces new Sideguard stent; expands commercial operations

Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announces that an additional diameter has been added to the Sideguard® platform.

26 Oct 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Key findings from AstraZeneca's phase II studies of ticagrelor

Clinical Data commences patient enrollment in Stedivaze Phase III trial

First gene expression test for coronary artery disease

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Sudden cardiac death more predictable in men than women

Stem cell therapy to treat heart, lung and vascular diseases show positive results

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

Cappella commences evaluation of the Sideguard Coronary Sidebranch Stent & Delivery System

Phase I clinical study for ETC-1002 commenced

UOHI to receive $5.4M federal funds for development of new alternative radioisotope imaging tracers

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

Stereotaxis reports $13.3 million revenue for third quarter 2009

Statins may have negative effects on some cardiac patients, says study

John Simpson named the 2009 Distinguished Alumnus for his invention

Celsius RMT ThermoCool catheter of Stereotaxis receives CE Mark for distribution in the European market

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Treatment of angina patients with ivabradine reduces risk of cardiovascular death

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Cappella introduces new Sideguard stent; expands commercial operations

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in